Equities
  • Price (EUR)21.62
  • Today's Change0.10 / 0.46%
  • Shares traded0.00
  • 1 Year change-4.72%
  • Beta--
Data delayed at least 15 minutes, as of Jun 09 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sonic Healthcare Limited is an Australia-based healthcare provider. The Company is engaged in specialist operations in laboratory medicine / pathology, radiology, and primary care medical services, across operations in Australia, Europe, and North America. Its segments include Laboratory, Radiology and Other. The Laboratory segment provides pathology/clinical laboratory services in Australia, New Zealand, the United Kingdom, the United States of America, Germany, Switzerland and Belgium. The Radiology segment provides diagnostic imaging services in Australia. The Other segment includes medical center operations (IPN), occupational health services (Sonic HealthPlus), and other minor operations. Sonic Clinical Services (SCS) is the primary care division of the Company, which provides a range of health services. The Company's services are provided to medical practitioners, hospitals, community health services, and their collective patients. The Company has more than 120 radiology centers.

  • Revenue in AUD (TTM)8.67bn
  • Net income in AUD1.02bn
  • Incorporated1934
  • Employees41.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SHL:ASX since
announced
Transaction
value
Medical Laboratories DuesseldorfAnnounced26 Apr 202326 Apr 2023Announced-3.93%197.50m
Diagnosticum - PartG der Fachaerzte fuer Labormedizin der Fachaerzte fuer Mikrobiologie der Fachaerzte fuer Pathologie der Fachaerzte fuer Humangenetik Dr Scholz und PartnerAnnounced02 Apr 202302 Apr 2023Announced0.29%205.94m
Data delayed at least 20 minutes, as of Jun 09 2023 07:10 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.